Your session is about to expire
← Back to Search
Other
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Phase 2
Waitlist Available
Research Sponsored by NFlection Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through week 8
Summary
This trial tests a special cream called NFX-179 on patients with skin tumors known as cutaneous neurofibromas. The cream is applied to the skin and works by being absorbed to target the tumor cells.
Eligible Conditions
- Neurofibromatosis
- Neurofibroma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through week 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through week 8
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Assessment of Adverse Events
Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application
Safety and Tolerability of NFX-179 Gel Measured by Local Tolerability Assessment
Secondary study objectives
Change in Physician Assessment of Tumor Severity Score
Change in Subject Self-Assessment of Tumor Severity Score
Percent Change in cNF Tumor Volume (Cubic Millimeters)
+1 moreSide effects data
From 2021 Phase 2 trial • 48 Patients • NCT044356658%
Anxiety
8%
Basal cell carcinoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vehicle Arm (Placebo)
NFX-179 Gel Low (0.05%)
NFX-179 Gel Mid (0.15%)
NFX-179 Gel High (0.50%)
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: NFX-179 Gel MidExperimental Treatment1 Intervention
NFX-179 Gel for topical administration, once daily for 28 days
Group II: NFX-179 Gel LowExperimental Treatment1 Intervention
NFX-179 Gel for topical administration, once daily for 28 days
Group III: NFX-179 Gel HighExperimental Treatment1 Intervention
NFX-179 Gel for topical administration, once daily for 28 days
Group IV: Vehicle ArmPlacebo Group1 Intervention
Vehicle Gel, for topical administration, once daily for 28 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NFX-179 Gel
2020
Completed Phase 2
~50
Find a Location
Who is running the clinical trial?
NFlection Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
199 Total Patients Enrolled
Guy Webster, MD, PhDStudy DirectorNFlection Therapeutics